◆英語タイトル：Meiji Seika Pharma Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
◆商品コード：DATA904C2013
◆発行会社（調査会社）：
MarketLine
◆発行日：2018年7月
◆ページ数：102
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketLine社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
MarketLine社の概要はこちらでご確認いただけます。
Meiji Seika Pharma Co Ltd – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Summary
Marketline’s Meiji Seika Pharma Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Meiji Seika Pharma Co Ltd since January2007.
Synopsis
Marketline’s Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Key Highlights
This report includes Meiji Seika Pharma Co Ltd’s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Meiji Seika Pharma Co Ltd. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Scope
- Provides intelligence on Meiji Seika Pharma Co Ltd’s M&A, strategic partnerships and alliances, capital raising and private equity transactions.
- Detailed reports of various financial transactions undertaken by Meiji Seika Pharma Co Ltd and its subsidiaries since 2007.
- Information about key financial and legal advisors for Meiji Seika Pharma Co Ltd’s financial deals transactions.
- Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
Reasons to buy
- Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances.
- Form an independent opinion about Meiji Seika Pharma Co Ltd’s growth strategies through the organic and inorganic activities undertaken since 2007.
- Track your competitors’ business structure and growth strategies.
Table of Contents
COMPANY OVERVIEW AND KEY FACTS 2
TABLE OF CONTENTS 5
LIST OF TABLES 6
LIST OF FIGURES 6
TARGETS AND PARTNERS 7
MERGERS & ACQUISITIONS 8
Mergers and Acquisitions – Overview 8
Mergers and Acquisitions – Deal reports 9
PARTNERSHIP 18
Partnership – Overview 18
Partnership – Deal reports 19
APPENDIX 92
Contact Us 92
About MarketLine Financial Deals Database 92
Deal Definition and Methodology 94
About MarketLine 101
List of Tables
Table 1: Meiji Seika Pharma Co Ltd M&A volume and value trend (2014-YTD2018)
Table 2: Meiji Seika Pharma Co Ltd M&A activity by geography (2014-YTD2018)
Table 3: Meiji Seika Pharma Co Ltd partnership volume and value trend (2014-YTD2018)
Table 4: Meiji Seika Pharma Co Ltd partnership trend by key deal type (2014-YTD2018)
List of Figures
Figure 1: Meiji Seika Pharma Co Ltd M&A volume and value trend (2014-YTD2018)
Figure 2: Meiji Seika Pharma Co Ltd M&A activity by geography (2014-YTD2018)
Figure 3: Meiji Seika Pharma Co Ltd partnership volume and value trend (2014-YTD2018)
Figure 4: Meiji Seika Pharma Co Ltd partnership trend by key deal type (2014-YTD2018)
